Studi clinici su Obesità nello stato di Idaho
21 studi su Obesità cercano partecipanti presso sedi nello stato di Idaho.
Città nello stato di Idaho
Testo ufficiale dello studio (inglese)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07752979A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
In reclutamentoFase 3
Età da 8 a 18 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07253285Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07392190Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Boise, Meridian
In reclutamentoFase 3
Età da 45 a 99 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- High Desert Heart and Vascular, Meridian
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
In reclutamentoFase 3Volontari sani benvenuti
Età da 18 a 79 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07575399A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- High Desert Heart and Vascular PLLC, Meridian
- St. Luke's Idaho Cardiology Associates, Meridian
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
In reclutamentoFase 3
Età da 18 a 79 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT06390345A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Elite Clinical Trials, Blackfoot
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 lug 2026 · NCT07481630Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.